Tuesday, 20 Aug 2019

You are here

Gout Takeaways

The annual EULAR meeting just came to an end today. Rooms are gradually emptying out. People look both content to have updated their knowledge and relieved that four very busy days have concluded. Time to summarize.

It is incredible how much information can be shared in four short days at a meeting like this. Just pick a topic, day and time and voila! Take gout for example; I strolled through the poster aisle today and here’s what I learned:

  1. Most gout patients are quite noncompliant with their uric acid lowering therapy. As outlined in abstract sat0357, after one year of treatment only 42.7% still continue ULT. This same study concludes men, older patients and patients whose first prescriber was a rheumatologist were more persistent.

  2. Patients with other comorbidities tend to have worse outcomes. From the survey of physicians and patient chart audits in the US ( ABST sat0358) we learn that patients with gout and T2DM had longer mean duration of gout (63 vs 41 months), were more likely to have tophi (37% vs 20%), joint damage (24% vs 13%), and clinician-rated severe gout (27% vs 13%) than those without T2DM (all p<0.01). Patients with gout and T2DM were also more likely to receive ULT than those without T2DM (86% vs 71%; p<0.01), and yet perform worse in terms of outcomes. What causes that? Could it be additional comorbidities (cardiovascular disease, kidney disease, COPD, depression, diabetes, hyperlipidemia, hypertension)? Same authors conclude patient with gout and T2DM vs. those without T2DM reported more office visits (4.1 vs 3.5), were more likely to have an emergency department visit (17% vs 9%) and were more likely to have a hospitalisation (5% vs 2%) (all p<0.01). What do we learn from these results? Patients with gout and other comorbidities would certainly benefit from more aggressive gout management.

  3. Next in line, a study on evolution of kidney function in gout after introduction of ULT ( sat 0359). In this study after ULT, mean eGFR differed significantly:+2.6 [IC95%: −0.279; 5.484; p=0.08],+3 [IC95%: 0.167; 5.794; p=0.04] and +2,7 [IC95%: 0.490; 4.960; p=0.02] ml/min/1,73 m2. Most efficacy was seen in patients with baseline GFR at the level of CKD stage 3 and higher. As a result, the rationale is to treat high sUA as soon as possible.

I could go on and on for hours listing all of the great educational materials presented during this meeting. If you could not attend, follow us on rheumnow.com. All you need is your laptop or mobile device, and you can enjoy the meeting through the eyes of RheumNow reporters. 

That's all for now. See you at the next meeting. 

Add new comment

More Like This

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Allopurinol Fails to Curtail Hypertension

A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.

Updated 2018 EULAR Recommendations for the Diagnosis of Gout

The first EULAR recommendations for the diagnosis of gout were published in 2006. A task force was formed and following a systematic review, they voted unanimously for changes in all items of the 2006 recommendations.

Excess Non-CV Mortality Persists in Gout

Patients with gout not only have a well-recognized increased risk of dying from cardiovascular (CV) disease, but also have higher all-cause mortality and die prematurely from other diseases, a Swedish study indicated.